Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Friday following insider selling activity. $111.50 million flowed into the stock on the tick-up and $145.73 million flowed out of the stock on the tick-down, for a money net flow of $34.23 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 19th highest net out-flow for the day. Johnson & Johnson traded up $0.04 for the day and closed at $145.34Specifically, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the sale, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at approximately $7,969,915.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Joaquin Duato sold 40,000 shares of the stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $144.36, for a total value of $5,774,400.00. Following the sale, the insider now directly owns 112,848 shares in the company, valued at $16,290,737.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 85,340 shares of company stock worth $11,992,396. 0.22% of the stock is currently owned by insiders.
Several analysts have recently issued reports on the company. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 target price on shares of Johnson & Johnson in a report on Friday, September 14th. Jefferies Financial Group set a $145.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Sunday, July 15th. HC Wainwright reissued a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Credit Suisse Group set a $149.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, October 14th. Finally, ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Hold” and a consensus price target of $142.54.
The company has a debt-to-equity ratio of 0.46, a current ratio of 1.72 and a quick ratio of 1.40. The stock has a market capitalization of $382.50 billion, a price-to-earnings ratio of 19.91, a price-to-earnings-growth ratio of 2.23 and a beta of 0.58.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be given a dividend of $0.90 per share. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a dividend yield of 2.48%. Johnson & Johnson’s dividend payout ratio is currently 49.32%.
Institutional investors have recently bought and sold shares of the business. Selective Wealth Management bought a new position in Johnson & Johnson in the third quarter valued at about $105,000. Financial Gravity Wealth Inc. bought a new position in shares of Johnson & Johnson during the first quarter worth about $105,000. CSat Investment Advisory L.P. bought a new position in shares of Johnson & Johnson during the second quarter worth about $107,000. WP Advisors LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $108,000. Finally, FNY Investment Advisers LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $117,000. Hedge funds and other institutional investors own 66.60% of the company’s stock.
About Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: How does inflation affect different investments?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.